X4 Pharmaceuticals (XFOR) Share-based Compensation (2017 - 2025)
X4 Pharmaceuticals' (XFOR) quarterly Share-based Compensation came in at $2.3 million in Q4 2025, up 2.44% YoY from $2.2 million in Q4 2024, and up 198.82% on a QoQ basis from $760000.0 in Q3 2025.
X4 Pharmaceuticals (XFOR) Share-based Compensation (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of Share-based Compensation data on file, last reported at $2.3 million in Q4 2025.
- Quarterly Share-based Compensation rose 2.44% year-over-year to $2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.3 million (down 47.61% YoY) and the FY2025 annual result came in at $4.3 million, down 47.61% from the prior year.
- Share-based Compensation rose to $2.3 million in Q4 2025, from $760000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $5.2 million in Q4 2022 to a low of -$3.0 million in Q3 2022.
- A 5-year average of $1.7 million and a median of $1.8 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation sank 295.84% — and 2023, when it surged 13608.33%.
- Tracing XFOR's Share-based Compensation over 5 years: stood at $1.6 million in 2021, then soared by 222.37% to $5.2 million in 2022, then slumped by 51.05% to $2.5 million in 2023, then dropped by 12.68% to $2.2 million in 2024, then increased by 2.44% to $2.3 million in 2025.
- The last three Share-based Compensation figures came in at $2.3 million (Q4 2025), $760000.0 (Q3 2025), and $748000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.27 Mn |
| Dec 31, 2025 | 2.27 Mn |
| Sep 30, 2025 | 760,000.00 |
| Sep 30, 2025 | 760,000.00 |
| Jun 30, 2025 | 748,000.00 |
| Jun 30, 2025 | 748,000.00 |
| Mar 31, 2025 | 519,000.00 |
| Mar 31, 2025 | 519,000.00 |
| Dec 31, 2024 | 2.22 Mn |
| Dec 31, 2024 | 2.22 Mn |
| Sep 30, 2024 | 1.82 Mn |
| Sep 30, 2024 | 1.82 Mn |
| Jun 30, 2024 | 2.43 Mn |
| Jun 30, 2024 | 2.43 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 2.54 Mn |
| Dec 31, 2023 | 2.54 Mn |
| Sep 30, 2023 | 2.36 Mn |
| Sep 30, 2023 | 2.36 Mn |